After years of preparing my body and ensuring stability, I am excited to announce that we are pregnant! I am thankful because I believe my hard work has played a role in our success and our immense joy right now.
Site Search
The U.S. Food and Drug Administration has approved the use of Kalydeco® (ivacaftor) for infants with cystic fibrosis as young as four months who have certain mutations.
Watch our vlog to hear us discuss the physical and emotional components of going through in-vitro fertilization (IVF), with a special focus on the female perspective.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.
Becoming pregnant after a lung transplant is possible, but is associated with increased complications. Learning more about post-transplant pregnancy can help you understand the potential risks and health implications.
The U.S. Food and Drug Administration (FDA) announced that it has approved Ultresa™ delayed-release capsules, a pancreatic enzyme replacement therapy. Ultresa (pancrelipase) is manufactured by Aptalis Pharma.
Delayed puberty is common among young men with CF, but working with your CF care team to ensure you get good nutrition can help encourage healthy development and growth.
By understanding the effects that different forms of contraception can have on people with cystic fibrosis, you can choose the method that is right for you.